Sentence examples for comparing denosumab data from inspiring English sources

Cowen warn against comparing denosumab data to the results for other drugs.

Recently, NNT analyses were performed using skeletal-related event data from two Phase III clinical trials comparing denosumab with zoledronic acid for treating bone metastases in patients with castration-resistant prostate cancer or other solid tumors (excluding breast cancer).

Results comparing denosumab with a placebo in fracture prevention are expected later this year.

The large phase III trials in metastatic bone disease comparing denosumab with zoledronic acid have completed accrual and will report in the next year.

For the results comparing denosumab with alendronate, three key variables were identified: age older than 70 years, a T-score of −3.5 or less, and previous fracture.

4, 5, 9, 65 A combined analysis of the three Phase III trials comparing denosumab with zoledronic acid in patients with bone metastases confirms these rates of osteonecrosis of the jaw and showed that, as of October 2010, osteonecrosis of the jaw resolved in 36% of patients (40% for denosumab versus 30% for zoledronic acid).

55 In a phase II study, McClung et al compared denosumab with placebo and alendronate in postmenopausal women with low BMD.

The safety and efficacy of denosumab were evaluated in a double-blind Phase III trial comparing denosumab with zoledronic acid – the standard of care for delaying SREs in metastatic castration-resistant prostate cancer patients.

A long-term follow-up of the breast cancer incidence in women who had received denosumab for 3 years in the FREEDOM trial [ 6] may corroborate this hypothesis, and recent results from a study comparing denosumab with zoledronic acid in women with advanced breast cancer indicate superiority of denosumab in preventing skeletal-related events [ 11].

Moreover, this study reported a higher incidence of osteonecrosis of the jaw with denosumab compared with other denosumab trials in patients with advanced cancer (5% versus 2%).

12 However, the rate of renal adverse events was similar for zoledronic acid compared with denosumab in patients with castration-resistant prostate cancer.